MEN1 and acute lymphoblastic leukemia: Novel treatment strategies, such as immunotherapy (e.g., blinatumomab [128]), BH3 mimetics agents, and menin inhibitors (as well as their combinations) have recently emerged as promising therapeutic approaches for this very difficult-to-treat ALL subtype (Table 1).